You just read:

Janssen Reports Switching to SYMTUZA™ Results in Maintained High Virologic Suppression and No Resistance Development up to 96-Weeks in Virologically Suppressed Adults with HIV-1

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Oct 03, 2018, 16:01 ET